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Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) as gefitinib emerged as an accepted treatment in second- or
third-line setting in NSCLC. However, clinical surrogate markers of EGFR-TKI activity in NSCLC patients remain to be identified and
we studied the prognostic value of CYFRA 21-1 in this setting. Serum samples from 53 patients with NSCLC receiving gefitinib after
failure of at least a platinum-containing regimen were prospectively collected from January 2002 to December 2003. Multivariate
analysis demonstrated an independent negative impact on survival for a level of CYFRA 21-1 higher than 3.5ngml
 1 (HR¼2.45, 95%
CI 1.13–5.29; P¼0.02). In conclusion, CYFRA 21-1 is a tool available to predict the survival of NSCLC patients receiving gefitinib as
third-line therapy in an independent manner. In case of a CYFRA 21-1 level higher than 3.5ngml
 1, treatment with gefitinib needs
further evaluation giving its relative poor effect on survival.
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The prognostic value of CYFRA 21-1 for non-small-cell lung cancer
(NSCLC) patients was recently definitively demonstrated in a
meta-analysis in 2063 patients (Pujol et al, 2004). In the same time,
epidermal growth factor receptor (EGFR) tyrosine kinase inhibi-
tors (TKI) as gefitinib emerged as an accepted treatment in
second- or third-line setting in NSCLC (Pfister et al, 2004).
However, clinical surrogate markers of EGFR-TKI activity in
NSCLC patients after failure of platinum-containing regimen
remain to be identified. So, we conducted a study of the prognostic
value of CYFRA 21-1 in NSCLC patients receiving gefitinib after
failure of platinum-containing regimen in an expanded access
program.
PATIENTS AND METHODS
Serum samples from patients with NSCLC receiving gefitinib after
failure of at least a platinum-containing regimen were prospec-
tively collected from January 2002 to December 2003. Histological
subclassification was carried out according to the World Health
Organization classification. Performance Status was estimated
using the Eastern Cooperative Oncology Group (ECOG) scale.
Clinical examination, chest, abdomen and brain-computed tomo-
graphic scan were carried out systematically.
Serum samples were obtained from each patient before gefitinib
therapy. Fresh serum was collected and cooled after sampling, and
then stored at  201C until analysis. All assays were performed
using commercial kit (ELSA CYFRA 21-1 CisBiointernationalt)
blind to clinical information. Serum level of CYFRA 21-1 was
considered as elevated when it was superior or equal to
3.5ngml
 1. Cutoff value of 3.5ngml
 1 for CYFRA 21-1 was based
on previously published results (Reinmuth et al, 2002). All patients
consented to treatment with gefitinib.
Survival data were updated in June 2004. One patient was lost.
Probability of survival was estimated using the Kaplan–Meier
method. Differences between survival were tested by means of log-
rank test. A multivariate regression analysis was carried out with
Cox’s regression using the forward maximum-likelihood method.
All variables with a P-value less than 0.20 at the time of univariate
analysis were entered into the model. A P-value less than 0.05 was
considered as significant.
RESULTS
In all, 53 patients were included in the study (Table 1). Two
patients did not received gefitinib due to disease progression and
were excluded from analysis. The median age of the 51 patients
was 60 years (38–78 years). All the patients were current or former
smokers. All the patients received a two-drugs platinum-contain-
ing regimen as first line of treatment. A total of 47 (92.1%) received
a third-generation drug regimen (gemcitabine, docetaxel or
paclitaxel) in both first- and second-line therapy. A skin toxicity
of grade 1 and 2 occurred for 11 (21.6%) and two (3.9%) patients,
respectively. Diarrhoea occurred for eight patients (15.7%). The
median duration of treatment was 3.3 months. The disease control
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srate was 70.6%, with 11.7% of partial response and 58.9% of stable
disease. At the time of analysis, 33 patients were deceased. The
median survival time was 4 months (1 to 20þ months).
The principal results of univariate analysis are shown in Table 2.
Multivariate analysis demonstrated an independent favourable
impact on survival for occurrence of a skin reaction (HR¼0.28,
95% CI 0.12–0.66; P¼0.004) and an independent negative impact
on survival for a level of CYFRA 21-1 higher than 3.5ngml
 1
(HR¼2.45, 95% CI 1.13–5.29; P¼0.02).
DISCUSSION
This study highlights the role of CYFRA 21-1 level in assessing
prognosis of NSCLC patients receiving gefitinib as third-line
therapy (HR for death is 2.45 for patients with CYFRA 21-1 level
higher than 3.5ngml
 1, P¼0.02). Giving this result, CYFRA 21-1
could be used as a help in determining patients who beneficiate
from treatment with gefitinib. This could be of a paramount
importance giving the lack of clinical factors in this setting.
Whereas genetic mutations on EGFR gene receptor were
identified in tumours of patients responding to gefitinib (Lynch
et al, 2004; Paez et al, 2004), we also need more easily assessable
and clinically available predictive factors for response to gefitinib
for daily practice. Using commercial kit, CYFRA 21-1 is easily
assessable and its role as prognostic marker alone (Pujol et al,
2004) or in combination (Barle ´si et al, 2004) has been demon-
strated. Furthermore, the prognostic value of CYFRA 21-1 in the
present study was higher than that of clinical (performance status,
weight loss) or biological (leucocytes, liver enzymes) traditional
prognostic markers. In addition, previous studies interested in
clinical (gender, Karnofsky index) or biological (EGFR expression,
HER2 expression) factors predictive for response or survival for
patients treated with gefitinib reported contradictive or negative
results, except for those with adenocarcinoma histological subtype
and nonsmoking history, which predict a better survival (Miller
et al, 2004). Likewise, skin rash has been suggested to predict
response to gefitinib as we have shown in our multivariate
analysis; however, available data do not definitively support this
hypothesis (van Zandwijk, 2003).
In conclusion, CYFRA 21-1 is a tool available to predict survival
of NSCLC patients receiving gefitinib as third-line therapy in an
independent manner. So, CYFRA 21-1 should be integrated in the
biological assessment of NSCLC patients prior to receiving
gefitinib. In case of a CYFRA 21-1 level higher than 3.5ngml
 1,
treatment with gefitinib needs further evaluation giving its relative
poor effect on survival.
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Table 1 Major clinical and biological factors of the study population
n (%)
Age o70/X70 years 38 (74.5)/13(25.5)
Gender women/men 16 (31.4)/35 (68.6)
Performance status 0–1/X2 (ECOG) 37 (72.5)/14 (27.5)
45% weight loss 11 (21.6)
Histology
Squamous cell carcinoma 15 (29.4)
Adenocarcinoma 24 (47.1)
Large-cell carcinoma 12 (23.5)
Stage
a IIIB/V 13 (25.5)/38 (74.5)
Chemotherapy regimens before gefitinib
2 30 (58.8)
3 15 (29.4)
X4 6 (11.8)
Leucocytes (Gl
 1) o10.5/X10.5 42 (82.4)/9 (17.6)
LDH (IUl
 1) o500/X500 37 (72.5)/14 (27.5)
Calcium level (mmoll
 1) o2.75/X2.75 48 (94.1)/3 (5.9)
Hepatic enzymes level (UIl
 1) o2 ULN/X2 ULN 46 (90.2)/5 (9.8)
CYFRA 21-1 level (ngml
 1) o3.5/X3.5 38 (74.5)/13 (25.5)
aUICC classification; LDH¼lactate dehydrogenase; ULN¼upper limit of the normal
range; ECOG¼Eastern Cooperative Oncology Group.
Table 2 Results of univariate analysis (only factors with Po0.02 were
reported)
Median survival
(months) P-value
PS o2/X2 7/2 0.0541
Weight loss (yes/no) 2/6 0.0568
Hepatic enzymes level o2 ULN/X2 ULN 4/2 0.1165
CYFRA 21-1 level (ngml
 1) o3.5/X3.5 7/2 0.0208
Leucocytes (Gl
 1) o10.5/X10.5 4/2 0.1723
Skin reaction (yes/no) 15/3 0.0056
PS¼performance status (ECOG); ULN¼upper limit of the normal range.
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